Clinical Trials Logo

Clinical Trial Summary

This study would assess the clinical efficacy of add-on topical timolol 0.5% gel to betamethasone valerate 0.1% for the treatment of EGFR-TKI induced paronychia. Eligible patients, who develop paronychia (affecting fingernails, toenails or both), will be included in this study. They will be randomized in 1:1 ratio using computer-generated randomization list to receive either combination of topical timolol 0.5% gel and betamethasone valerate 0.1% lotion application twice daily or betamethasone valerate 0.1% lotion application twice daily. Patients in timolol combination treatment group will receive topical timolol 0.5% gel twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% lotion twice daily with occlsuion for 1 month. Patients in routine arm would receive the management according to routine clinical practice, including prescription of betamethasone valerate 0.1% lotion twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks , up to 12 weeks to see the effect.


Clinical Trial Description

The aim of this study ist o assess the clinical efficacy of add-on topical timolol 0.5% gel to betamethasone valerate 0.1% for the treatment of EGFR-TKI induced paronychia. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06140186
Study type Interventional
Source Queen Mary Hospital, Hong Kong
Contact Wang Chun Kwok, MBBS
Phone +852 2255 5336
Email herbert728@gmail.com
Status Recruiting
Phase Phase 3
Start date April 1, 2023
Completion date March 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT06411093 - Efficacy and Safety of Kinesiology Tape Wrapping for Paronychia Induced by Epidermal Growth Factor Receptor Inhibitors N/A
Recruiting NCT03908892 - Effect of Zanthoxylum Nitidum Tincture for Paronychia Caused by Afatinib N/A
Recruiting NCT05639933 - Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors Phase 2
Completed NCT05165082 - The Efficacy of Topical Timolol Combined With Cryotherapy in EGFR Inhibitors-induced Paronychia - a Double-blinded, Intrapatient Left-to-right Controlled Study N/A